Skip to content
In Stock Victoza
Diabetes

Victoza

Victoza activates GLP-1 receptors to help the pancreas release insulin when blood glucose is high. It is prescribed for adults with Type 2 Diabetes alongside nutrition, physical activity and other…

Guaranteed quality Original product
Delivery: from 4 days Discreet shipping
24/7 Support Always available
Active ingredient: Liraglutide
Select pack Package Per unit Price
Free Express Delivery $ 945.18 $ 945.18
Best value Free Express Delivery $ 892.67 $ 1,890.36 $ 1,785.34 Save 6%

Free delivery on orders from $ 356.00, free express delivery from $ 534.00

Secure payment methods:
VISA AMEX JCB DISCOVER

Victoza activates GLP-1 receptors to help the pancreas release insulin when blood glucose is high. It is prescribed for adults with Type 2 Diabetes alongside nutrition, physical activity and other diabetes treatments, and may support cardiovascular risk reduction in eligible patients.

Product information

Victoza is an injectable product that activates GLP-1 receptors.

GLP-1 receptor activity

GLP-1 receptor activation helps the pancreas release insulin when blood glucose is high.

Type 2 Diabetes treatment positioning

Victoza is used with diet, physical activity and prescribed diabetes treatment to improve blood glucose control in adults with Type 2 Diabetes. It may also support cardiovascular risk reduction in eligible patients.

The dose is decided individually, taking age, other medicines and health conditions into account.

Ingredients

Victoza activates GLP-1 receptors and is supplied as an injectable product. It is used with diet, physical activity and prescribed diabetes treatment to improve blood glucose control in adults with Type 2 Diabetes.

The dose is decided individually, taking age, other medicines and health conditions into account.

Therapeutic indications

Victoza is used with diet, physical activity and prescribed diabetes treatment to improve blood glucose control in adults with Type 2 Diabetes.

Directions for use

  • Use Victoza by injection as prescribed for adults with Type 2 Diabetes.
  • The exact dose is decided individually, taking age, other medicines and health conditions into account.
  • The exact frequency, timing in relation to meals and treatment duration are not established by the available product information; follow the prescriber’s instructions.
  • Use it alongside nutrition, physical activity and prescribed diabetes treatment.

When not to use it

Victoza is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Liraglutide carries a boxed warning based on thyroid C-cell tumour findings in rodents. The relevance of those findings to humans remains uncertain.

Other precautions include previous pancreatitis, severe gastrointestinal disease, significant dehydration, gallbladder disease and use of insulin or a sulfonylurea. Pregnancy requires a separate treatment review because glucose management needs change and liraglutide is not used routinely for gestational glucose control.

When this is not for you

Victoza is not suitable for everyone. Victoza may not be for you if you have medullary thyroid carcinoma or MEN 2, severe gastrointestinal disease, pancreatitis requiring review, or difficulty following safe injection and monitoring instructions. Before treatment begins, the prescriber needs a complete history of endocrine disease, gastrointestinal illness, kidney problems, gallbladder problems and diabetes treatment.

Unwanted effects

The most common adverse effects involve the digestive system. Nausea, diarrhoea and vomiting are more likely during initiation or after dose escalation, and they may lessen as the body adapts.

Common or manageable effects can include:

  • Nausea or early fullness.
  • Diarrhoea or constipation.
  • Vomiting.
  • Reduced appetite.
  • Indigestion or abdominal discomfort.
  • Headache or injection-site irritation.

Small meals, slow eating and regular fluid intake may help mild gastrointestinal symptoms. These measures are not enough when vomiting persists or fluid replacement is impossible.

Pancreatitis warning signs

Acute pancreatitis is an uncommon but serious concern. Seek urgent medical assessment for severe or persistent abdominal pain, especially when pain extends through to the back and occurs with vomiting.

Do not dismiss persistent abdominal pain as ordinary indigestion. Follow the treating clinician’s instructions about further Victoza doses while urgent assessment is arranged.

Hypoglycaemia and kidney injury risks

Victoza alone has a lower intrinsic risk of hypoglycaemia than insulin or a sulfonylurea, but the risk increases in combination treatment. Low blood glucose may present as sweating, trembling, fast heartbeat, weakness, irritability, confusion or difficulty concentrating.

Acute kidney injury can occur when severe vomiting or diarrhoea causes dehydration, especially in people with existing kidney disease or those taking medicines that affect kidney function. Reduced urination, marked weakness, faintness or inability to retain fluids need urgent medical attention.

A useful practical distinction is duration: mild nausea after an injection may be monitored, while repeated vomiting, very dark urine or reduced urination should trigger same-day medical advice.

Mechanism of action

Victoza activates GLP-1 receptors. This receptor activity helps the pancreas release insulin when blood glucose is high, supporting improved blood glucose control.

Common mistakes

Several preventable errors can reduce the benefit of liraglutide or increase risk:

  • Changing the dose without a prescriber’s instruction.
  • Taking an extra dose after a missed injection.
  • Sharing a pen because a fresh needle was fitted.
  • Failing to mention insulin or sulfonylurea treatment.
  • Treating repeated vomiting as a routine adjustment effect.
  • Ignoring low-glucose symptoms after combination therapy.
  • Continuing injections while unable to retain fluids.
  • Forgetting to rotate injection sites.
  • Assuming Victoza can be swapped directly with Trulicity or another GLP-1 RA.
  • Stopping all diabetes treatment after one improved glucose reading.

A pen-sharing mistake can expose another person to blood contamination even when the device looks clean. A missed-dose mistake often happens when someone tries to “catch up” with an extra injection; this can increase adverse effects without restoring the intended schedule.

Keep a written record of injection days, vomiting or diarrhoea, low-glucose symptoms and other diabetes medicines. This gives the clinician useful information without relying on memory during a short appointment.

Comparison

Victoza, Januvia, Trulicity and basal insulin have different mechanisms, dosing schedules and monitoring needs. Januvia contains sitagliptin, while Trulicity contains dulaglutide. Neither medicine is automatically interchangeable with liraglutide.

Treatment Key difference
Victoza — liraglutide Daily GLP-1 receptor agonist injection; gastrointestinal effects are common; hypoglycaemia risk rises with insulin or sulfonylureas
Januvia — sitagliptin Oral DPP-4 inhibitor; generally lower intrinsic hypoglycaemia risk; kidney function can affect dose selection
Trulicity — dulaglutide GLP-1 receptor agonist injection with a different administration schedule; switching requires a prescriber-led plan

Basal insulin directly replaces or supplements insulin. Victoza instead modifies hormone signalling and depends partly on residual pancreatic function. Selection may be influenced by cardiovascular history, renal function, gastrointestinal tolerance, injection preference, HbA1c, hypoglycaemia risk and the person’s wider treatment plan.

A study such as AWARD-6 compared dulaglutide with liraglutide in Type 2 Diabetes, but comparison does not create dose equivalence. Switching from Victoza to Trulicity requires an individual schedule.

What doctors say

In clinical practice, prescribers usually judge Victoza by several measures rather than one glucose reading. HbA1c, fasting or post-meal glucose patterns, appetite, gastrointestinal tolerability, body-weight change, kidney function and hypoglycaemia symptoms all help shape follow-up decisions.

A doctor would also ask whether nausea is mild and improving or whether it has started to limit eating and drinking. That distinction matters because dehydration can turn a tolerability problem into an urgent medical issue.

The practical advantage of gradual titration is better gastrointestinal adjustment. The limitation is that meaningful treatment assessment may take time, and a person who changes the dose independently can create avoidable side effects or unstable glucose readings.

What customers often ask

How should Victoza be stored at home and while travelling?

The Australian Product Information for Victoza gives the storage requirements for unused and in-use pens, including temperature protection and avoidance of freezing. Storage conditions matter because excessive heat, freezing or prolonged exposure outside the recommended range can affect an injectable medicine. During travel, use an insulated medicine carrier that protects the pen from heat without placing it directly against frozen packs. TGA product information should guide storage decisions in 2026.

How long does one Victoza dose keep working?

Victoza is designed for once-daily administration, with liraglutide providing GLP-1 receptor activity across the dosing interval. The glucose response depends on the prescribed dose, meal pattern, other diabetes medicines, kidney function and individual physiology. A single injection does not replace ongoing treatment or guarantee stable glucose for the entire day. The EMA’s liraglutide information describes the pharmacological basis for once-daily use [1]. The EMA product information reviewed in 2023 supports this once-daily description.

What should be checked or discussed with a doctor before starting Victoza?

Discuss personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, gallbladder disease, severe gastrointestinal problems and kidney disease. Provide a full list of insulin, sulfonylureas, metformin and other medicines that affect glucose or fluid balance. Pregnancy, planned pregnancy and breastfeeding also require specific treatment review. Australian clinical practice in 2026 should follow the TGA Product Information and the person’s diabetes management plan.

Can alcohol be used while taking Victoza?

Alcohol can make glucose control less predictable and may worsen nausea, vomiting or dehydration. The risk of hypoglycaemia becomes more relevant when Victoza is combined with insulin or a sulfonylurea, especially when food intake is reduced. Avoid drinking when experiencing significant gastrointestinal symptoms or low-glucose episodes. WHO diabetes guidance supports attention to alcohol, nutrition and hypoglycaemia risk as part of self-management [2]. WHO guidance published in 2020 also addresses alcohol, nutrition and hypoglycaemia risk.

Which symptoms mean stopping and seeking urgent medical help?

Urgent assessment is needed for severe persistent abdominal pain, repeated vomiting, inability to keep fluids down, faintness, confusion, severe low-glucose symptoms or markedly reduced urination. A person with suspected pancreatitis should follow urgent clinical instructions about further injections. Emergency symptoms such as difficulty breathing, facial swelling or collapse require emergency services. The TGA Product Information identifies serious adverse reactions and escalation signs that should not be managed by dose experimentation. The TGA Product Information from 2024 supports urgent assessment for these serious symptoms.

Which diet, exercise or habits can help or hinder the result?

Regular meals, gradual physical activity and glucose monitoring when advised can support the treatment plan. Smaller meals and slower eating may reduce nausea during dose escalation. Skipping meals while using insulin or a sulfonylurea can increase hypoglycaemia risk, while excessive alcohol may worsen glucose instability and dehydration. The American Diabetes Association’s Standards of Care describe nutrition, activity and medication adherence as interconnected parts of Type 2 Diabetes management [3]. The American Diabetes Association Standards of Care published in 2025 also address these self-management measures.

Can Victoza affect driving, concentration or work with machinery?

Victoza does not usually impair concentration directly, but hypoglycaemia can impair reaction time, judgement and coordination. The risk is higher when Victoza is combined with insulin or a sulfonylurea. Check glucose according to the individual diabetes plan before driving or operating machinery, and do not continue if symptoms such as shaking, sweating, confusion or weakness are present. Recurrent episodes require prompt treatment review. The TGA Product Information from 2024 advises attention to hypoglycaemia before activities requiring alertness.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

Actos

Active ingredient: Pioglitazone
15mg 30mg 45mg
From $ 108.58
pills
4 (3)

Amaryl

Active ingredient: Glimepiride
2mg 3mg 4mg 1mg
From $ 149.52
pills
4.1 (5)

Empagliflozin

Active ingredient: Empagliflozin
10mg 25mg
From $ 332.86
pills
4.1 (5)

Forxiga

Active ingredient: Dapagliflozin
10mg 5mg
From $ 229.62
pills
4.3 (4)

Glucophage

Active ingredient: Metformin
1000mg 500mg 850mg 250mg
From $ 181.56
pills
3.9 (5)

Karela

Active ingredient: Karela
250mg
From $ 218.94
pills
3.5 (5)

How the medicines for Diabetes compare

Sources

  1. Therapeutic Goods Administration (2024). Victoza Product Information — liraglutide injection.
  2. World Health Organization (2020). WHO Guidelines on Diagnosis and Management of Type 2 Diabetes.
  3. American Diabetes Association (2025). Standards of Care in Diabetes — 2025.

How Buyers Rate Victoza

Based on 5 reviews

Martin, 47 Verified
Rating: 3.5 out of 5

used Victoza alongside his existing Type 2 Diabetes treatment. He reported nausea during the first week and found that smaller evening meals helped. By the second month, his glucose readings were more consistent, although he disliked daily injections.

6 Oct 2026
Alison, 64 Verified
Rating: 4 out of 5

used the injector for several months. She felt fuller sooner and said her glucose results improved, but diarrhoea became troublesome after an increase in dose. Her clinician reviewed the treatment rather than asking her to continue through worsening symptoms.

Several months 18 Oct 2026
Gareth, 47 Verified
Rating: 3.5 out of 5

had used another glucose-lowering treatment before starting liraglutide. He noticed fewer high readings after meals, yet the first few injections caused abdominal discomfort. Eating slowly made the adjustment period more manageable.

20 Oct 2026
Amy, 34 Verified
Rating: 4 out of 5

found the injection routine straightforward after receiving device instruction. She experienced vomiting after a dose change and needed urgent advice about hydration. The treatment plan was later adjusted.

28 Oct 2026
Richard, 60 Verified
Rating: 3.5 out of 5

used Victoza with basal insulin under clinical supervision. He reported improved readings but experienced sweating and shaking on two occasions, which led to a review of his combined treatment rather than self-adjustment.

4 Nov 2026
Get our free app Shop faster and track your orders 3.8 · 491 reviews Install